Generation Bio explores strategic alternatives, workforce cut ~90%, Q2 net loss $20.9M

Generation Bio Co.

New ctLNP data shows selective siRNA delivery to T cells in NHPs at 0.5 mg/kg dose; lead siRNAs target LAT1 and VAV1.
Company evaluating strategic alternatives (acquisition, merger, etc.) with TD Cowen; no timetable set.
Implementing ~90% workforce reduction in phases from mid-August to end of October 2025.
Q2 2025 net loss $20.9M ($3.12/share); cash $141.4M at June 30; expects ~$100M post lease settlement.
Litigation with Waltham landlord resolved with $31M lump sum; extinguishes $58M lease liability in Q3.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.